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GLUCOSAMINEVS PLACEBO INTHETREATMENT OF
OSTEOARTHRITIS: META-ANALYSIS
O’Leary BA1, Glase KM1,Adena M2, Hutchinson RS2
1Covance Pty Ltd, Sydney, NSW, Australia, 2Covance Pty Ltd,
Canberra, ACT, Australia
OBJECTIVES: To determine the efﬁcacy of glucosamine by con-
ducting a meta-analysis of double blinded, randomised, con-
trolled trials (RCTs) comparing glucosamine with placebo.
METHODS: Published RCTs were identiﬁed from the Cochrane
review and a literature search of Medline, Embase and the
Cochrane Clinical Trials Register. The outcomes examined were
change in mean and minimum joint space narrowing (JSN),
WOMAC (Western Ontario and McMaster Universities Arthritis
Index) (pain, function and stiffness and total) and the Lequesne
Index. The WOMAC scales were adjusted to a common scale.
Key exclusion criteria were: non-oral administration, no out-
comes of interest, <20 patients and non-English publication. The
ten studies comprised seven using glucosamine sulphate, two,
glucosamine hydrochloride, and one, salt not stated. Duration of
followup was <=2 weeks in ﬁve studies, 12–26 weeks in three
studies and three years in two studies. Where possible, the data
were analysed on an intent-to-treat basis. Usually, this involved
extrapolating missing data, as would occur for patients who
discontinued from the trial, by using the last valid value for that
patient. RESULTS: The estimates (95% conﬁdence interval,
p-value) of the random-effects meta-analysis of glucosamine vs
placebo were: JSN mean, mm (2 studies): 0.24 (0.11, 0.36),
0.0001; JSN minimum, mm (1 study): 0.33 (0.11, 0.55), 0.003;
WOMAC total (7 studies): -2.05 (-3.72, -0.38), 0.02; WOMAC
pain (7 studies): -0.36 (-0.84, 0.12), 0.14; WOMAC function (7
studies): -1.72 (-2.95, -0.50), 0.006; WOMAC stiffness (6
studies): -0.09 (-0.28, 0.10), 0.36; Lequesne Index (5 studies):
-2.02 (-3.18, -0.85), 0.0007. Glucosamine was statistically sig-
niﬁcantly better than placebo for JSN, total WOMAC and func-
tion subscale and the Lequesne Index. Similar results for
WOMAC pain and stiffness subscales did not reach statistical
signiﬁcance. CONCLUSION: The meta-analysis indicates that
glucosamine improves outcomes in osteoarthritis.
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OBJECTIVES: To determine whether race inﬂuences a patient’s
likelihood of being prescribed selective cyclooxygenase-2 inhi-
bitors (COX-2s) versus other nonsteroidal anti-inﬂammatory
agents (NSAIDs) in Medicaid managed care plans (MCOs).
METHODS: All medical and prescription claims for MCO
enrollees receiving at least one prescription for a COX-2 or
NSAID between January 2000 and June 2002 were retrieved.
Selected for study were adults claiming at least one COX-2
prescription or NSAID prescription with a minimum 30 days
supply after June 2000; having 60 total days of supply or more
over the study period was also required for study inclusion. The
probability of being a COX-2 user was estimated as a logistic
function of patient age, gender, race, city/suburban/rural resi-
dence, and history of rheumatoid arthritis, osteoarthritis, chronic
back pain, acute pains, gastrointestinal problems, and comor-
bidities (hypertension, hyperlipidemia, obesity, diabetes, renal
problems, alcohol/tobacco/drug abuse, cardiovascular events).
RESULTS: Sample COX-2 users numbered 4349 and NSAID
users numbered 13,489. Half were African-American, three-
quarters were female, and a third was over 50 years old. After
adjusting for confounders, African-American and other races
were a third less likely to be COX-2 users than Caucasians (OR,
0.66; 95% CI, 0.61–0.72). Residence in Baltimore was an addi-
tional factor reducing COX-2 usage (OR, 0.87; 95%CI, 0.80–
0.95). Gender was not a signiﬁcant factor. Age and all clinical
covariates but diabetes was signiﬁcant predictors at the 0.05
level. CONCLUSION: Race signiﬁcantly affected access to
COX-2 medication in Medicaid MCOs, even after adjusting for
other demographic and clinical variables. Cost to the patient
was not a factor, as the patient co-payment was $1 for any
prescription.
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COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS
PATIENTS IN ARGENTINA
Solé JP1, Ortega GP1, Kielhorn A2
1Productos Roche S.A.Q.e I, Buenos Aires, Argentina, 2F. Hoffmann-La
Roche AG, Basel, Switzerland
OBJECTIVES: Rituximab (RTX; MabThera) is available in
Argentina for the treatment of rheumatoid arthritis (RA) in
patients refractory to tumour necrosis factor (TNF) inhibition.
Evidence suggests that response to RTX is inﬂuenced by the
number of prior TNF inhibitors [1]. This study evaluates the
cost-beneﬁt ratio of current biologic therapies and determines
the cost-beneﬁt impact of introducing RTX following one or
more TNF inhibitors. METHODS: Prices were taken from three
different pharmacies, DroFar, Social Congresso, Scienza, Jan
2007 ($US1 = $ARS3.12; €1 = $ARS4.05). Average annual treat-
ment costs (drug treatment and administration) were determined
over a three year period. ACR20 response rate was chosen as the
measure of beneﬁt. Using pivotal trial data, unadjusted for dif-
ferent placebo response, the percentage of patients achieving an
ACR20 response rate was: RTX + MTX, 58%; INFL + MTX,
50%; ADAL + MTX, 63% and ETAN + MTX, 71%. ACR20
response rates for RTX were 58%, 51% and 42% after an
inadequate response to 1, 1.5 and 2 TNF inhibitors respectively.
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